Popular Articles

World's First Cardiac Adult Stem Cell Patient Receives Infusion
Michael (Mike) Jones has become the world"s first recipient of adult cardiac stem cells to treat congestive heart failure. Jones" infusion on July 17 marks the world"s first phase-one FDA-approved clinical trial using adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital.
buy viagra
Catalyst Pharmaceutical Partners Announces Top-Line Results Of CPP-109 Phase II Trial For Cocaine Addiction
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint -- that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free during the last two weeks of the treatment period (Weeks 11 and 12). The clinical trial did not reveal any unexpected "serious" adverse events.
News of the day
Medtronic-Supported Clinical Trial Shows ICD Patients Less Likely To Develop Need For Pacing When Device Uses MVP(R) Mode
MVP® (Managed Ventricular Pacing), exclusive programming on Medtronic pacemakers, which is proven to be effective in reducing unnecessary pacing in pacemaker patients, was applied in the MVP Trial of implantable cardioverter-defibrillator (ICD) patients. Data from MVP trial, sponsored by Medtronic, Inc. (NYSE: MDT), were presented today as a late breaking clinical trial at Heart Rhythm 2009, the annual scientific sessions of the Heart Rhythm Society.
Nutrition

Study Sees Transient Heart Dysfunction In Some Long-Distance Runners

A new study using advanced cardiac imaging technology indicates that cardiac abnormalities experienced by some marathon runners following competition are temporary, and do not result in damage to the heart muscle. The study, conducted by researchers at the University of Manitoba, marked the first use of cardiac magnetic resonance imaging, or CMR, in a post-marathon setting. The research was presented on Sunday, May 17, at the 105th International Conference of the American Thoracic Society in San Diego. "Although previous studies of marathon runners have demonstrated biochemical evidence of cardiac injury and have correlated these findings with echocardiographic evidence of cardiac dysfunction, this was the first time CMR has been used to further evaluate and understand the effects of marathon running on the heart," said study investigator Davinder S. Jassal, M.D., assistant professor of cardiology, radiology and physiology at St. Boniface General Hospital Research Centre in Winnipeg. The study examined the cardiac health of 14 runners who participated in the full 2008 Manitoba Marathon in Winnipeg, Canada. All runners were classified, for purposes of the study, as "non-elite," meaning they participated on a casual, non-professional basis, with limited or no training. Prior to the marathon, each study participant underwent a comprehensive health screening, including blood tests to determine the levels of cardiac biomarkers, factors present in the blood that reflect the health of the heart muscle. Following the race, additional blood samples were taken and echocardiograms and CMR were performed. Earlier studies have confirmed that cardiac biomarkers are elevated in many casual, non-professional athletes following competition, indicating possible damage to the heart muscle. In this study, echocardiograms and CMR performed immediately after competition revealed abnormalities, including irregularities in diastolic filling (relaxation abnormalities) on both sides of the heart and a decrease from 64 percent to 43 percent in the pumping function of the right ventricle. Although the cardiac biomarkers were elevated post marathon, there was no evidence of direct permanent injury to the heart muscle on CMR imaging. "By using CMR, we were able to definitively show that these fluctuations do not result in any true damage of the heart, and the right ventricular dysfunction is transient, recovering one week following the race," Dr. Jassal noted. The researchers are planning additional studies to determine whether these abnormalities may result in permanent damage in runners who participate in more than one marathon during a 12-month period. Keely Savoie American Thoracic Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):